Gilead Sciences, Inc. - Product Pipeline Review - 2015

  • ID: 3280640
  • Company Profile
  • 142 pages
  • Global Markets Direct
  • Gilead Sciences Inc
1 of 4
Gilead Sciences, Inc. - Product Pipeline Review - 2015

Summary

This, ‘Gilead Sciences, Inc. - Product Pipeline Review - 2015’, provides an overview of the Gilead Sciences, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Gilead Sciences, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Gilead Sciences, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Gilead Sciences, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Gilead Sciences, Inc.’s pipeline products

Reasons to buy

- Evaluate Gilead Sciences, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Gilead Sciences, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Gilead Sciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Gilead Sciences, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Gilead Sciences, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Gilead Sciences, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables
List of Figures
Gilead Sciences, Inc. Snapshot
Gilead Sciences, Inc. Overview
Key Information
Key Facts
Gilead Sciences, Inc. - Research and Development Overview
Key Therapeutic Areas
Gilead Sciences, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Gilead Sciences, Inc. - Pipeline Products Glance
Gilead Sciences, Inc. - Late Stage Pipeline Products
Gilead Sciences, Inc. - Clinical Stage Pipeline Products
Gilead Sciences, Inc. - Early Stage Pipeline Products
Gilead Sciences, Inc. - Drug Profiles
(elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide)
(emtricitabine + tenofovir alafenamide)
(ledipasvir + sofosbuvir)
(emtricitabine + rilpivirine hydrochloride + tenofovir alafenamide)
(sofosbuvir + GS-5816)
ambrisentan
GS-6615
idelalisib
momelotinib dihydrochloride
ranolazine ER
tenofovir alafenamide
(GS-9857 + GS-5816 + sofosbuvir)
(ranolazine hydrochloride + dronedarone hydrochloride)
acalisib
GS-4774
GS-4997
GS-5745
GS-9256
GS-9620
GS-9669
GS-9973
ONO-4059
presatovir
Px-102
Px-104
regadenoson
simtuzumab
vedroprevir
GS-5829
GS-6637
GS-9857
GS-9883
GS-9901
velpatasvir
AB-0045
GS-548202
GS-5759
GS-607601
GS-8374
GS-967
Monoclonal Antibodies 1 for Cancer
Px-103
Small Molecule to Inhibit Histone Deacetylation for Cancer
Small Molecule to Inhibit Histone Methyltransferase for Cancer
GS-563253
GS-599220
Monoclonal Antibody for HIV / AIDS
Small Molecule to Inhibit NS4B Protein for HCV
Small Molecules to Inhibit NS3 Protease for Hepatitis C
Gilead Sciences, Inc. - Pipeline Analysis
Gilead Sciences, Inc. - Pipeline Products by Target
Gilead Sciences, Inc. - Pipeline Products by Route of Administration
Gilead Sciences, Inc. - Pipeline Products by Molecule Type
Gilead Sciences, Inc. - Pipeline Products by Mechanism of Action
Gilead Sciences, Inc. - Recent Pipeline Updates
Gilead Sciences, Inc. - Dormant Projects
Gilead Sciences, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Gilead Sciences, Inc. - Company Statement
Gilead Sciences, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Gilead Sciences, Inc., Key Information
Gilead Sciences, Inc., Key Facts
Gilead Sciences, Inc. - Pipeline by Indication, 2015
Gilead Sciences, Inc. - Pipeline by Stage of Development, 2015
Gilead Sciences, Inc. - Monotherapy Products in Pipeline, 2015
Gilead Sciences, Inc. - Combination Treatment Modalities in Pipeline, 2015
Gilead Sciences, Inc. - Partnered Products in Pipeline, 2015
Gilead Sciences, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
Gilead Sciences, Inc. - Out-Licensed Products in Pipeline, 2015
Gilead Sciences, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
Gilead Sciences, Inc. - Pre-Registration, 2015
Gilead Sciences, Inc. - Phase III, 2015
Gilead Sciences, Inc. - Phase II, 2015
Gilead Sciences, Inc. - Phase I, 2015
Gilead Sciences, Inc. - Preclinical, 2015
Gilead Sciences, Inc. - Discovery, 2015
Gilead Sciences, Inc. - Pipeline by Target, 2015
Gilead Sciences, Inc. - Pipeline by Route of Administration, 2015
Gilead Sciences, Inc. - Pipeline by Molecule Type, 2015
Gilead Sciences, Inc. - Pipeline Products by Mechanism of Action, 2015
Gilead Sciences, Inc. - Recent Pipeline Updates, 2015
Gilead Sciences, Inc. - Dormant Developmental Projects,2015
Gilead Sciences, Inc. - Discontinued Pipeline Products, 2015
Gilead Sciences, Inc., Other Locations
Gilead Sciences, Inc., Subsidiaries

List of Figures
Gilead Sciences, Inc. - Pipeline by Top 10 Indication, 2015
Gilead Sciences, Inc. - Pipeline by Stage of Development, 2015
Gilead Sciences, Inc. - Monotherapy Products in Pipeline, 2015
Gilead Sciences, Inc. - Combination Treatment Modalities in Pipeline, 2015
Gilead Sciences, Inc. - Partnered Products in Pipeline, 2015
Gilead Sciences, Inc. - Out-Licensed Products in Pipeline, 2015
Gilead Sciences, Inc. - Pipeline by Top 10 Target, 2015
Gilead Sciences, Inc. - Pipeline by Top 10 Route of Administration, 2015
Gilead Sciences, Inc. - Pipeline by Top 10 Molecule Type, 2015
Gilead Sciences, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll